

Ionizable Amphiphilic Dendrimer-Based Nanomaterials with Alkyl-Chain-Substituted Amines for Tunable siRNA Delivery to the Liver Endothelium In Vivo**

Omar F. Khan, Edmond W. Zaia, Hao Yin, Roman L. Bogorad, Jeisa M. Pelet, Matthew J. Webber, Iris Zhuang, James E. Dahlman, Robert Langer, and Daniel G. Anderson*

Abstract: A library of dendrimers was synthesized and optimized for targeted small interfering RNA (siRNA) delivery to different cell subpopulations within the liver. Using a combinatorial approach, a library of these nanoparticle-forming materials was produced wherein the free amines on multi-generational poly(amido amine) and poly(propyleneimine) dendrimers were substituted with alkyl chains of increasing length, and evaluated for their ability to deliver siRNA to liver cell subpopulations. Interestingly, two lead delivery materials could be formulated in a manner to alter their tissue tropism within the liver—with formulations from the same material capable of preferentially delivering siRNA to 1) endothelial cells, 2) endothelial cells and hepatocytes, or 3) endothelial cells, hepatocytes, and tumor cells in vivo. The ability to broaden or narrow the cellular destination of siRNA within the liver may provide a useful tool to address a range of liver diseases.

RNA interference (RNAi) is the process whereby a small interfering RNA (siRNA) induces the degradation of complementary mRNA gene transcripts, thus silencing genes.^[1] A key need to the broad application of RNAi is the development of safe and effective delivery systems capable of silencing genes in specific cells within the body. This type of selectivity has the potential to focus therapy, and thereby decrease side effects. Nanoformulation of siRNA is one approach toward this end, and to date the most advanced strategies are hepatocyte-specific, having both selectivity and potency in nonhuman primates and clinical trials.^[2] There is an increasing collection of reports of siRNA delivery to

tissues other than hepatocytes including tumors,^[3] immune cells,^[4] and the endothelium.^[5] However, delivery to these other tissues is often nonspecific, with siRNA functionally delivered to more than just the target tissue. Here we report on the development of formulations based on dendrimeric materials in which the targeting is tuned through modifying formulation parameters. Particular focus was placed on developing new delivery materials capable of silencing genes in different liver cell subpopulations, with special emphasis placed on blood vessel endothelial cells.


The chemically modified dendrimer materials were synthesized using Michael addition chemistry by combining poly(amido amine) or poly(propyleneimine) dendrimers of increasing generations with alkyl epoxides of various carbon chain lengths, as illustrated in Scheme 1. The resulting branched, amine-rich ionizable dendrimer cores facilitate efficient complexation with negatively charged siRNA under acidic formulation conditions. Modification of the dendrimers with alkyl chains affords lipid-like properties, promoting particle formation through hydrophobic aggregation in aqueous conditions. Whereas polycationic polymers for siRNA delivery materials are generally polydisperse and often possess random branching,^[6] these modified dendrimers can be molecularly defined, with monodisperse dendrimer cores and defined branching. Poly(amido amine) and poly(propyleneimine) dendrimers have been previously investigated for their utility in siRNA delivery.^[7] However, the alkyl modification reported here allows for the formation of lipid-like nanoparticles with additional lipid components (excipients).

[*] Dr. O. F. Khan, E. W. Zaia, Dr. H. Yin, Dr. R. L. Bogorad, Dr. J. M. Pelet, Dr. M. J. Webber, Dr. J. E. Dahlman, Prof. R. Langer, Prof. D. G. Anderson
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA 02139 (USA)
E-mail: dgander@mit.edu
I. Zhuang
Department of Biology, Massachusetts Institute of Technology
Cambridge, MA 02139 (USA)
Prof. R. Langer, Prof. D. G. Anderson
Harvard-MIT Division of Health Sciences and Technology
Department of Chemical Engineering
and
Institute for Medical Engineering and Science
Massachusetts Institute of Technology
Cambridge, MA 02139 (USA)

[**] The authors thank Dr. Carmen Barnes, Dr. Yizhou Dong, and J. Robert Dorkin for useful advice. Special thanks to MIT's Division of Comparative Medicine and Swanson Biotechnology Center. Funding was provided by the National Institutes of Health Centers of Cancer and Nanotechnology Excellence (U54 CA151884), the United States Army Medical Research and Materiel Command's Armed Forces Institute of Regenerative Medicine (W81XWH-08-2-0034), and Alnylam Pharmaceuticals. R.L. is a shareholder and member of the Scientific Advisory Board of Alnylam. R.L. and D.G.A. have sponsored research grants from Alnylam. O.F.K. designed experiments and performed all work with the assistance of other authors.



Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201408221>.



Scheme 1. Synthesis of chemically modified dendrimer materials. Epoxide-terminated alkyl chains ranging in size from C_{10} to C_{16} were reacted with the free amines on poly(amido amine) or poly(propyleneimine) dendrimers of increasing generation size. In this example, PG0, or generation 0 poly(amido amine), is reacted with an alkyl epoxide.

These excipients can be used to further tune the properties and activity of the resulting dendrimer.

Products were purified by flash chromatography to remove any unreacted starting materials. The products contained a mixture of different substitution patterns as well as chiral isomers when examined by thin layer chromatography ($0.4 < R_f < 0.8$ for a 87.5:11:1.5 $CH_2Cl_2/MeOH/NH_4OH_{aq}$ solvent system). These materials were screened for siRNA delivery using a HeLa cell line that stably expressed both firefly and Renilla luciferase.^[8] Modified dendrimer nanoparticles were complexed with siRNA against firefly luciferase at a 5:1 mass ratio of modified dendrimer to siRNA. The Renilla luciferase was used as an internal viability control. For this initial high-throughput screen, modified dendrimers were only formulated with 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-*N*-[methoxy(polyethylene glycol)-2000] ($C_{14}PEG_{2000}$), at a 4:1 molar ratio of modified dendrimer to $C_{14}PEG_{2000}$. As shown in Figure 1a, all evaluated dendrimers demonstrated significant reduction in the expression of firefly luciferase when compared to PBS-treated controls, with the differential activity dependent on the specific chemistry used. Nanoparticle uptake into HeLa cells was verified using confocal microscopy for dendrimers formulated with Cy5.5-labelled siRNA (Figure 1b,c).

Modified dendrimers were validated *in vivo* for the simultaneous delivery of siRNA to both liver endothelial cells and hepatocytes. Using the same formulation conditions as in the initial *in vitro* screen, modified dendrimers were co-formulated with two siRNAs against *tie2* and Factor VII (FVII). *Tie2* was selected as a target for silencing because it is an endothelial cell-specific target gene.^[9] FVII, meanwhile, has been previously established as a robust target for hepatocyte-specific delivery.^[8,10] After co-formulation, modified dendrimer nanoparticles were injected into the tail veins of healthy 8-week-old female C57BL/6 mice. After two days, mice were euthanized, and *tie2* gene and FVII protein levels were quantified (Figure 2a).

Based on their ability to simultaneously silence genes in both liver endothelial cells and hepatocytes, PG1.C12 and PG1.C15 were selected as the top performing materials. These two materials had an identical core consisting of the first generation poly(amido amine) dendrimer (i.e., PG1), but




Figure 1. a) Representative subset of the full *in vitro* screen of modified dendrimers showing HeLa luciferase luminescence after knockdown of firefly luciferase at a 25 nM siRNA dose. Renilla luminescence was used as an internal control to both gauge off-target effects and modified dendrimer-induced toxicity. Dendrimers (including a lipofectamine positive control) are listed on the x axis and luciferase luminescence is shown on the y axis. P = poly(amido amine), D = diaminobutane amine poly(propyleneimine)tetramine, G# = generation number, C# = number of carbons in the alkyl chain. N = 3 and error bars are \pm S.D. b,c) Confocal images of PG1.C12 (b) and PG1.C15 (c) nanoparticle delivering Cy5.5-labelled siRNA into HeLa cells at a 50 nM dose. Color code: red, nanoparticles; green, cell membrane; blue, nuclei. Scale bar = 10 μ m.

varied in the length of the substituted alkyl chains (i.e., C_{12} versus C_{15} ; refer to Scheme S1, and Figures S1 and S2 in the Supporting Information, SI). PG1.C15 nanoparticles were larger in diameter and more resistant to degradation in blood serum (Figures S3 and S4, respectively, SI). The apparent nanoparticle pK_a values of the two lead materials were ≥ 5.5 (Figure S5 and Table S1, SI). Previous studies have shown that apparent nanoparticle pK_a values ≥ 5.5 often correlate to hepatocyte delivery,^[11] which corresponds to the findings reported here. The lead materials' affinity for the liver was further confirmed and visualized by biodistribution studies (Figure S6, SI). *Tie2* knockdown was also quantified in the endothelium of other organs, but the effect was most potent in the liver (Figure S7, SI). Moreover, no significant silencing was observed in immune cell populations when these materials were complexed with siRNA against the pan-leukocyte marker CD45 (Figure S8, SI).

To establish the relative potency of siRNA delivery to endothelial cells and hepatocytes, a dose response was generated with both PG1.C12 and PG1.C15 nanoparticles. In these experiments, particles were co-formulated with FVII and *tie2* siRNA (Figure 2b). As was done in the initial *in vivo* screens, these co-formulated particles used $C_{14}PEG_{2000}$ as the only excipient. As shown in Figure 2b, a significant knockdown of *tie2* in the liver endothelium was achieved with an siRNA dose of 1 mg kg⁻¹, whereas a similar degree of FVII




Figure 2. a) An example of an in vivo multigenerational modified dendrimer screen using $C_{14}PEG_{2000}$ as the only formulation excipient. Modified dendrimer nanoparticles were co-formulated with tie2 and FVII siRNAs. The total siRNA dose was 3.7 mg kg^{-1} ; 1.2 mg kg^{-1} of FVII siRNA and 2.5 mg kg^{-1} tie2 siRNA. The co-formulated particles simultaneously caused knockdown of both genes in the liver two days after tail vein injection. b) In vivo performance of PG1.C12- and PG1.C15-modified dendrimer nanoparticles co-formulated with tie2 and FVII siRNAs two days after tail vein injection. $C_{14}PEG_{2000}$ was the only excipient. For the higher dose, a total siRNA dose of 1.125 mg kg^{-1} (1 mg kg^{-1} tie2 siRNA and 0.125 mg kg^{-1} FVII siRNA) was used. The lower dose had a total siRNA dose of 0.51 mg kg^{-1} (0.5 mg kg^{-1} tie2 siRNA and 0.01 mg kg^{-1} FVII siRNA). $* = p < 0.04$ (t-test) for comparison between doses. c,d) Optimized nanoparticles containing $C_{14}PEG_{2000}$ and cholesterol as excipients were co-formulated with FVII and tie2 siRNAs. The combined siRNA dose was 2.6 mg kg^{-1} ; 2.5 mg kg^{-1} tie2 siRNA and 0.1 mg kg^{-1} FVII siRNA. Expression was measured two days after tail vein injections. $N = 3$ and $* = p < 0.02$ for comparison between formulations. c) Both formulations of PG1.C15 resulted in tie2 knockdown in liver endothelial cells. However, the low excipient 98:1:1 formulation stopped delivery to hepatocytes. d) Both PG1.C12 formulations caused knockdown in the liver endothelium, while the low excipient 97:1:2 formulation prevented hepatocyte delivery. e,f) The reduced excipient formulations that resulted in hepatocyte exclusion also increased the mean size of the nanoparticles and reduced their polydispersity. All error bars are \pm S.D.

knockdown was observed using only an siRNA dose of 0.125 mg kg^{-1} . Because these nanoparticles were formulated

siRNA showed no knockdown for any of the tested formulations in either cell type (Figure S9, SI). Interestingly,

to contain both siRNAs, the difference in siRNA efficiency for each gene indicates that both nanoparticle formulations had a higher silencing potency in hepatocytes, and a reduced potency in liver endothelial cells. Thus, in order to compensate for the reduced potency in the liver endothelium, a higher loading of the desired endothelium-specific siRNA would be required for a strategy designed to silence both endothelial and hepatic gene expression to the same extent.

After establishing which siRNA doses were necessary for gene knockdown in endothelial cells and hepatocytes, we next sought to boost nanoparticle performance through changes in the formulation. Cholesterol is an important component in the lipid envelope of viruses^[12] and has been used in many potent nanoparticle formulations.^[2a–c] Thus, we sought to evaluate the effects of altering the amount of cholesterol in these formulations. For the studies, the total dose of siRNA as well as the ratio of tie2:FVII siRNA were kept constant and only the cholesterol composition was varied. Moreover, the siRNA dose used in these studies was informed by previous experiments (Figure 2b) to control differences in siRNA efficiency between the two cell types. Figure 2c shows that PG1.C15 nanoparticles formulated at a 90:2:8 mass ratio of modified dendrimer/cholesterol/ $C_{14}PEG_{2000}$ targeted both hepatocytes and liver endothelial cells, as was seen previously in cholesterol-free formulations. However, when the amount of cholesterol and $C_{14}PEG_{2000}$ was reduced to achieve a 98:1:1 formulation ratio, the same nanomaterial demonstrated an increased potency and specificity in liver endothelial cells and a significantly reduced potency in hepatocytes. Similarly, endothelial-specific targeting with reduced hepatocyte potency was seen for the PG1.C12 when the formulation was changed from 89:2:9 to 97:1:2, though the efficiency of PG1.C12 as a delivery material is not as high as that of PG1.C15 (Figure 2d). Negative controls for nanoparticles formulated with a nonfunctional scrambled

nanoparticles in the endothelial-specific formulations were larger in diameter than those that did not demonstrate similar selectivity (Figure 2e,f). Although all of the modified dendrimer nanoparticles evaluated here resulted in no dramatic increase in blood plasma cytokine levels at 48 h following administration, formulations with higher cholesterol content resulted in fewer fluctuations in cytokine levels relative to the baseline (Figure S10; SI).

Therefore, though the PG1.C12 and PG1.C15 modified dendrimers both can enable simultaneous delivery of siRNAs to multiple liver cell types, they can be formulated such that the potency of delivery to hepatocytes is reduced whereas the delivery to endothelial cells is maintained or enhanced. This was achieved by co-formulating with cholesterol as an additional excipient in the nanoparticles, while maintaining a constant 5:1 mass ratio for modified dendrimer/siRNA. Depending on the ratio of cholesterol and C₁₄PEG₂₀₀₀ in the formulations, the targeted liver cell subpopulation can be varied.

After investigating gene silencing in the endothelial cells and hepatocytes of normal, nondiseased livers, silencing was examined in liver tumor cells. Liver tumors contain a heterogeneous mixture of cells, including cancerous cells, normal hepatic cell types, and endothelial cells.^[13] Using the minimal excipient formulation (4:1 modified dendrimer/C₁₄PEG₂₀₀₀ molar ratio and 5:1 modified dendrimer/siRNA mass ratio), PG1.C12 and PG1.C15 were evaluated for delivery to hepatocellular carcinoma cells in Met-driven tumors.^[14] Unlike normal adult hepatocytes, tumor cells in these hepatocellular carcinomas specifically express and secrete alpha-fetoprotein (AFP) into the blood.^[15] Thus, as a model system for delivery to hepatocellular carcinoma, modified dendrimer nanoparticles formulated with siRNA for AFP were evaluated in this Met-driven AFP-expressing tumor model. As shown in Figure 3, PG1.C12 and PG1.C15 showed a 51% and 92% knockdown, respectively, of AFP at a 1 mg kg⁻¹ dose. Thus, in the context of these two lead materials, changing the length of the substituted alkyl chains adds an additional formulation guideline for delivery to various liver cell types. At the siRNA doses and ratios reported here, cholesterol-free formulations of PG1.C12 preferentially silenced genes in endothelial cells and healthy hepatocytes, and reduced silencing in the tumors. In contrast, cholesterol-free formulations of PG1.C15 increased the silencing in tumor cells but had similar efficacy in endothelial cells and healthy hepatocytes at the same dose (Figures 2b and 3b).

This work describes the potential to bias silencing to multiple tissues, including the liver endothelium, hepatocellular carcinoma cells, and hepatocytes, in a controlled and tunable way by formulation. With the two lead modified dendrimers presented here, preferential silencing can be influenced by varying the excipient ratio and changing the length of substituted alkyl chains. Nanoparticle formulations with higher endothelial cell selectivity were larger in diameter (Figure 2e,f). These larger sizes may have played a role in the selective delivery by affecting the transport of nanoparticles through the fenestrated endothelium of the liver, thus reducing hepatocyte access and uptake.^[16] Furthermore, the




Figure 3. a) Serum protein Western blot showing in vivo alpha-fetoprotein (AFP) knockdown in hepatocellular carcinoma cells using PG1.C12- and PG1.C15-modified dendrimers. Nanoparticles were formulated at a 4:1 modified dendrimer/C₁₄PEG₂₀₀₀ molar ratio and a 1 mg kg⁻¹ siRNA dose was used. b) Densitometry analysis of the blot showed that both modified dendrimers caused a significant decrease in the amount of AFP in the blood. PG1.C15 was the more potent of the two formulations. N=3, error bars are 1 S.D. and connecting lines indicate a significant difference ($p < 0.05$, t-test).

changes in excipient content may have altered blood serum protein adsorption to the nanoparticles, which may have in turn altered liver cell subpopulation uptake. Lipid-based nanoparticles are known to exchange components with the serum and adsorb proteins.^[17] Apolipoprotein E is a serum protein that can adsorb to nanoparticles and enhance uptake into hepatocytes.^[18] Thus, one hypothesis is that the endothelium-specific formulations reduce their affinity for apolipoprotein E, which may subsequently diminish hepatocyte uptake and gene knockdown.

With regard to hepatocellular carcinoma gene silencing efficiency, a number of factors, including particle size, charge, stability, and retention time, may have contributed to the observed difference in potency. Although these modified dendrimers contained the same core, the lengths of their substituted alkyl chains differed; PG1.C12 had C₁₂ alkyl chains while PG1.C15 had longer C₁₅ chains. Once formulated, PG1.C15 nanoparticles were larger and more stable in blood serum (Figures S3 and S4, SI). The increased serum stability may have increased the circulation time of the intact nanoparticles, allowing them more time to reach their target. Moreover, the larger size of the PG1.C15 nanoparticles may have improved their retention time within the tumor.^[19] Additionally, as indicated by zeta potential data (Table S1, SI), PG1.C15 nanoparticles were more prone to aggregation. Perhaps, after nanoparticle entry into the tumor, their effective size increased through accretion, which possibly enhanced nanoparticle retention even further.

The ability to bias delivery to liver endothelial cells may prove useful when the target genes are expressed in both hepatocytes and endothelial cells, but therapy requires only silencing in the endothelium. A potential example of this could include the treatment of inflamed liver endothelium,

which often occurs in liver disease. In contrast, it is possible that delivery to both hepatocytes and endothelium could be useful when diseases affect both tissues, such as in the case of ischemia/reperfusion injuries caused by liver surgery and transplantation.^[20]

Alkyl substitution of regularly branched dendrimer structures to produce amphiphiles rich with primary, secondary, and tertiary amines is a facile strategy to prepare nanoparticles that can condense siRNA for targeted delivery. Moreover, the use of molecularly defined, regularly branched, ionizable dendrimers as the core structure for these materials is advantageous with respect to clinical translation. Future formulations of these materials could be considered for the delivery of other therapeutic nucleic acids, such as mRNA, microRNA, and DNA.

Received: August 13, 2014

Revised: October 3, 2014

Published online: October 29, 2014

Keywords: amphiphiles · dendrimers · drug delivery · nanomaterials · RNA

- [1] a) A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, C. C. Mello, *Nature* **1998**, *391*, 806–811; b) S. M. Elbashir, W. Lendeckel, T. Tuschl, *Genes Dev.* **2001**, *15*, 188–200.
- [2] a) Y. Dong, et al., *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 3955–3960; b) T. I. Novobrantseva, et al., *Mol. Ther. Nucleic Acids* **2012**, *1*, e4; c) K. T. Love, et al., *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 1864–1869; d) M. A. Maier, et al., *Mol. Ther.* **2013**, *21*, 1570–1578; e) M. Jayaraman, et al., *Angew. Chem. Int. Ed.* **2012**, *51*, 8529–8533; *Angew. Chem.* **2012**, *124*, 8657–8661; f) T. Coelho, et al., *N. Engl. J. Med.* **2013**, *369*, 819–829.
- [3] a) M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, *Nature* **2010**, *464*, 1067–1070; b) J. H. Park, G. von Maltzahn, M. J. Xu, V. Fogal, V. R. Kotamraju, E. Ruoslahti, S. N. Bhatia, M. J. Sailor, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 981–986; c) W. Xue, et al., *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E3553–E3561.
- [4] T. I. Novobrantseva, et al., *Mol. Ther. Nucleic Acids* **2012**, *1*, e4.
- [5] a) J. E. Dahlman, et al., *Nat. Nanotechnol.* **2014**, *9*, 648–655; b) A. Santel, et al., *Gene Ther.* **2006**, *13*, 1360–1370.
- [6] a) A. C. Richards Grayson, A. M. Doody, D. Putnam, *Pharm. Res.* **2006**, *23*, 1868–1876; b) A. Zintchenko, A. Philipp, A. Dehshahri, E. Wagner, *Bioconjugate Chem.* **2008**, *19*, 1448–1455; c) H. Katas, H. O. Alpar, *J. Controlled Release* **2006**, *115*, 216–225; d) D. W. Lee, K. S. Yun, H. S. Ban, W. Choe, S. K. Lee, K. Y. Lee, *J. Controlled Release* **2009**, *139*, 146–152; e) D. Jere, H.-L. Jiang, Y.-K. Kim, R. Arote, Y.-J. Choi, C.-H. Yun, M.-H. Cho, C.-S. Cho, *Int. J. Pharm.* **2009**, *378*, 194–200; f) Y. Inoue, R. Kurihara, A. Tsuchida, M. Hasegawa, T. Nagashima, T. Mori, T. Niidome, Y. Katayama, O. Okitsu, *J. Controlled Release* **2008**, *126*, 59–66; g) J. G. Li, D. Cheng, T. H. Yin, W. C. Chen, Y. J. Lin, J. F. Chen, R. T. Li, X. T. Shuai, *Nanoscale* **2014**, *6*, 1732–1740; h) K. Watanabe, M. Harada-Shiba, A. Suzuki, R. Gokuden, R. Kurihara, Y. Sugao, T. Mori, Y. Katayama, T. Niidome, *Mol. Biosyst.* **2009**, *5*, 1306–1310; i) Y. Nakayama, *Acc. Chem. Res.* **2012**, *45*, 994–1004.
- [7] a) Y. Omid, A. J. Hollins, R. M. Drayton, S. Akhtar, *J. Drug Targeting* **2005**, *13*, 431–443; b) O. Taratula, R. Savla, H. X. He, T. Minko, *Int. J. Nanotechnol.* **2011**, *8*, 36–52; c) A. Nomani, S. Fouladdel, I. Haririan, R. Rahimnia, M. Ruponen, T. Gazori, E. Azizi, *Afr. J. Pharm. Pharmacol.* **2012**, *6*, 530–537; d) M. L. Patil, M. Zhang, T. Minko, *ACS Nano* **2011**, *5*, 1877–1887; e) Y.-J. Tsai, C.-C. Hu, C.-C. Chu, I. Toyoko, *Biomacromolecules* **2011**, *12*, 4283–4290; f) T. Yu, X. Liu, A. L. Bolcato-Bellemin, Y. Wang, C. Liu, P. Erbacher, F. Qu, P. Rocchi, J. P. Behr, L. Peng, *Angew. Chem. Int. Ed.* **2012**, *51*, 8478–8484; *Angew. Chem.* **2012**, *124*, 8606–8612; g) S. Malhotra, et al., *Biomacromolecules* **2012**, *13*, 3087–3098.
- [8] A. Akinc, et al., *Nat. Biotechnol.* **2008**, *26*, 561–569.
- [9] a) J. D. Ramsden, H. C. Cocks, M. Shams, S. Nijjar, J. C. Watkinson, M. C. Sheppard, A. Ahmed, M. C. Eggo, *J. Clin. Endocrinol. Metab.* **2001**, *86*, 2709–2716; b) F. Arai, A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G. Y. Koh, T. Suda, *Cell* **2004**, *118*, 149–161; c) T. N. Sato, Y. Qin, C. A. Kozak, K. L. Audus, *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 9355–9358.
- [10] A. Akinc, et al., *Mol. Ther.* **2009**, *17*, 872–879.
- [11] K. A. Whitehead, et al., *Nat. Commun.* **2014**, *5*, 4277.
- [12] R. C. Aloia, H. Tian, F. C. Jensen, *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 5181–5185.
- [13] Y. Zhao, D. Y. Alakhova, A. V. Kabanov, *Adv. Drug Delivery Rev.* **2013**, *65*, 1763–1783.
- [14] A. D. Tward, K. D. Jones, S. Yant, S. T. Cheung, S. T. Fan, X. Chen, M. A. Kay, R. Wang, J. M. Bishop, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 14771–14776.
- [15] a) R. L. Bogorad, H. Yin, A. Zeigerer, H. Nonaka, V. M. Ruda, M. Zerial, D. G. Anderson, V. Kotliansky, *Nat. Commun.* **2014**, *5*, 3869; b) J. M. Llovet, A. Burroughs, J. Bruix, *Lancet* **2003**, *362*, 1907–1917.
- [16] D. C. Litzinger, A. M. J. Buiting, N. van Rooijen, L. Huang, *Biochim. Biophys. Acta Biomembr.* **1994**, *1190*, 99–107.
- [17] a) P. R. Cullis, A. Chonn, S. C. Semple, *Adv. Drug Delivery Rev.* **1998**, *32*, 3–17; b) A. Chonn, S. C. Semple, P. R. Cullis, *J. Biol. Chem.* **1992**, *267*, 18759–18765.
- [18] C. L. Bisgaier, M. V. Siebenkas, K. J. Williams, *J. Biol. Chem.* **1989**, *264*, 862–866.
- [19] A. Albanese, P. S. Tang, W. C. Chan, *Annu. Rev. Biomed. Eng.* **2012**, *14*, 1–16.
- [20] V. Kohli, M. Selzner, J. F. Madden, R. C. Bentley, P.-A. Clavien, *Transplantation* **1999**, *67*, 1099–1105.